Lipocine (NASDAQ:LPCN) Stock Price Passes Below 200 Day Moving Average After Earnings Miss

Lipocine Inc. (NASDAQ:LPCN) crossed below its 200-day moving average during trading on Thursday following a dissappointing earnings announcement. The stock has a 200-day moving average of $5.68 and traded as low as $2.34. Lipocine shares last traded at $2.39, with a volume of 71,207 shares.

The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.16 million. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.

Analyst Ratings Changes

LPCN has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research report on Friday, March 27th. Wall Street Zen downgraded shares of Lipocine from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $15.00.

Insider Activity

In other news, CEO Mahesh V. Patel bought 25,000 shares of the company’s stock in a transaction on Monday, April 6th. The stock was bought at an average cost of $2.03 per share, with a total value of $50,750.00. Following the transaction, the chief executive officer directly owned 160,679 shares in the company, valued at $326,178.37. The trade was a 18.43% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John W. Higuchi bought 123,000 shares of the company’s stock in a transaction on Monday, April 6th. The stock was purchased at an average cost of $2.05 per share, with a total value of $252,150.00. Following the completion of the transaction, the director owned 163,797 shares in the company, valued at $335,783.85. This represents a 301.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 213,000 shares of company stock valued at $434,600. 6.35% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Lipocine

Institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its stake in shares of Lipocine by 57.5% during the first quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after purchasing an additional 6,982 shares in the last quarter. AIGH Capital Management LLC acquired a new position in shares of Lipocine during the first quarter worth $1,598,000. Ikarian Capital LLC acquired a new position in shares of Lipocine during the fourth quarter worth $1,602,000. Squadron Capital Management LLC acquired a new position in shares of Lipocine during the fourth quarter worth $4,256,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Lipocine during the fourth quarter worth $441,000. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Price Performance

The business’s 50 day moving average is $5.30 and its 200 day moving average is $5.68. The stock has a market cap of $19.19 million, a price-to-earnings ratio of -1.42 and a beta of 0.50.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.